Focus Partners Advisor Solutions LLC Has $1.70 Million Stake in Natera, Inc. $NTRA

Focus Partners Advisor Solutions LLC grew its stake in Natera, Inc. (NASDAQ:NTRA) by 72.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,540 shares of the medical research company’s stock after buying an additional 4,421 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Natera were worth $1,697,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NTRA. JPMorgan Chase & Co. lifted its holdings in Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after purchasing an additional 3,263,822 shares during the last quarter. Norges Bank bought a new position in shares of Natera in the second quarter valued at approximately $277,749,000. AQR Capital Management LLC boosted its holdings in shares of Natera by 44.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock worth $291,717,000 after buying an additional 532,769 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Natera by 20.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after buying an additional 330,696 shares during the period. Finally, Holocene Advisors LP grew its stake in Natera by 118.3% in the 2nd quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company’s stock valued at $96,774,000 after buying an additional 310,452 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NTRA. Morgan Stanley lowered their price target on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. Guggenheim increased their price objective on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, January 5th. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Finally, UBS Group upped their target price on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $253.47.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the sale, the insider owned 144,992 shares of the company’s stock, valued at $34,035,422.08. The trade was a 13.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Herm Rosenman sold 48,419 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $227.42, for a total value of $11,011,448.98. Following the transaction, the director owned 20,342 shares of the company’s stock, valued at $4,626,177.64. This represents a 70.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 363,303 shares of company stock worth $84,523,079 over the last three months. 5.63% of the stock is currently owned by insiders.

Natera Stock Performance

Shares of NTRA stock opened at $197.14 on Friday. The firm has a fifty day moving average of $223.82 and a 200-day moving average of $204.71. The stock has a market cap of $27.94 billion, a price-to-earnings ratio of -128.85 and a beta of 1.65. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same quarter in the previous year, the firm posted ($0.41) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.